Legend Biotech (LEGN) Receivables (2019 - 2026)
Legend Biotech's (LEGN) quarterly Receivables came in at $1.7 million in Q1 2026, up 28.5% YoY from $1.3 million in Q1 2025, and down 87.02% on a QoQ basis from $13.1 million in Q4 2025.
Legend Biotech (LEGN) Receivables (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Receivables data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Receivables rose 28.5% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 28.5% YoY) and the FY2025 annual result came in at $13.1 million, up 82.45% from the prior year.
- Receivables eased to $1.7 million in Q1 2026, from $13.1 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $100.8 million in Q4 2023 to a low of $56000.0 in Q1 2023.
- A 5-year average of $22.6 million and a median of $7.2 million in 2024 frame the typical range for Receivables.
- The widest YoY moves for Receivables: up 9613.97% in 2023, down 99.89% in 2023.
- Tracing LEGN's Receivables over 5 years: stood at $1.0 million in 2022, then jumped by 9613.97% to $100.8 million in 2023, then slumped by 92.88% to $7.2 million in 2024, then jumped by 82.45% to $13.1 million in 2025, then slumped by 87.02% to $1.7 million in 2026.
- The last three Receivables figures came in at $1.7 million (Q1 2026), $13.1 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.70 Mn |
| Dec 31, 2025 | 13.10 Mn |
| Sep 30, 2025 | 2.40 Mn |
| Jun 30, 2025 | 28.63 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 7.18 Mn |
| Sep 30, 2024 | 2.61 Mn |
| Jun 30, 2024 | 14.93 Mn |
| Mar 31, 2024 | 4.38 Mn |
| Dec 31, 2023 | 100.83 Mn |
| Sep 30, 2023 | 48.35 Mn |
| Jun 30, 2023 | 61.75 Mn |
| Mar 31, 2023 | 56,000.00 |
| Dec 31, 2022 | 1.04 Mn |
| Mar 31, 2022 | 50.45 Mn |
| Dec 31, 2021 | 100.41 Mn |
| Sep 30, 2021 | 1.50 Mn |
| Jun 30, 2021 | 61,000.00 |
| Dec 31, 2020 | 150.00 Mn |
| Dec 31, 2019 | 30.28 Mn |